CompletedPhase 3NCT04711603

A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Studying Uremic pruritus

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Kissei Pharmaceutical Co., Ltd.
Principal Investigator: Yoshitaka Shimizu
Kissei Pharmaceutical Co., Ltd.
Intervention: MR13A9(drug)
Enrollment: 178 target
Eligibility: 20 years · All sexes
Timeline: 2021 – 2022

Study locations (1)

Research Site, Multiple Locations, Japan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04711603 on ClinicalTrials.gov

Other trials for Uremic pruritus

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT06446310
Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Qilu Pharmaceutical (Hainan) Co., Ltd.

See all trials for Uremic pruritus →

← Back to all trials